

Classification and epidemiologic analysis of 86 diseases in *China's Second List of Rare Diseases*

Junfeng Li¹, Meilin Liu^{1,§}, Han Li^{2,§}, Xin Zhang^{3,§}, Xufei Xiang^{1,§}, Yiping Wang^{1,§}, Shuyi Wang^{1,§}, Jinxiang Han^{1,4}, Yanqin Lu^{1,4,*}

¹ Key Laboratory for Biotech-Drugs of National Health Commission, Key Laboratory for Rare & Uncommon Diseases of Shandong Province, Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Shandong First Medical University & Shandong Academy of Medical Sciences, Ji'nan, China;

² Shandong Experimental High School, Ji'nan, China;

³ Digestive Diseases Hospital of Shandong First Medical University, Ji'ning, China;

⁴ Department of Endocrinology and Metabolism, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Ji'nan, China.

SUMMARY Following the release of *China's First List of Rare Diseases* in May 2018, the Chinese government officially published *China's Second List of Rare Diseases* in September 2023. To date, there is no unified standard and international consensus for rare diseases, and epidemiologic data for most rare diseases in China are lacking. We investigated 86 rare diseases on the second list using Orphanet and other databases to clarify the classification, nomenclature, and epidemiologic data for these diseases, and we summarized the genotype and phenotype of hereditary diseases. The results showed that most of 86 rare diseases were coded in the database of Unified Medical Language System (UMLS), Orphanet, Medical Subject Headings (MeSH) and International Classification of Diseases, Eleventh Revision (ICD-11). Some rare diseases are composed by group of different disorders, in which multiple identifiers existed. Meanwhile, some rare diseases have different subtypes, which correspond to different identifiers. This increases the actual number of rare diseases in the second list. Over 50% of rare diseases are genetic rare diseases and they are mainly classified into neoplastic diseases, transplant-related disorders and neurological diseases. Epidemiologic data indicated that these rare diseases had a broad prevalence spectrum and over 20 rare diseases had a prevalence of over 1/10,000, these rare diseases in the *China's Second List of Rare Diseases* expanded the number and scope of rare diseases according to the China's official definition of rare diseases.

Keywords *China's Second List of Rare Diseases*, classification, nomenclature, epidemiology, incidence, prevalence

1. Introduction

A rare disease is a health condition with low prevalence and incidence compared with other more prevalent diseases in the general population. Although these diseases are individually rare, over 7,000 conditions have been identified, which affect 3.5%-5.9% of individuals worldwide or an estimated 263-446 million individuals collectively (1). Rare diseases are a global public health issue. Patients with rare diseases face challenges regarding diagnosis, treatment, and care. Great advances have been made in the diagnosis, treatment, care, and epidemiology of rare diseases in China, and several policies have been enacted to ensure progress in the area of rare diseases (2,3).

Before China's official definition of rare diseases in 2021, five bodies including the National Health Commission of the People's Republic of China and the National Medical Products Administration issued *China's First List of Rare Diseases* in May 2018 (4,5). Five years later, *China's Second List of Rare Diseases* was officially released on 21 September 2023 by six bodies. Until now, 207 rare diseases have been included on this list. In September 2021, China defined rare diseases as a condition with at least one of the following three criteria: an incidence among newborns of less than 1/10,000, a prevalence of less than 1/10,000, and an affected population of less than 140,000 (6). Thus, the rare diseases list and this definition have now been simultaneously adopted in China.

There is no unified international standard and consensus to date on how rare diseases should generally be named and classified. The nomenclature of rare diseases is recorded using international terminologies in different reference databases. In this study, we investigated the classification, genetic information, incidence, and prevalence of 86 conditions in *China's Second List of Rare Diseases* using Orphanet, OMIM, and other databases.

2. Methods

The nomenclature of 86 conditions in *China's Second List of Rare Diseases* was retrieved using international terminologies in different reference databases, including ICD-10 (7) and ICD-11 (8) (<https://icd.who.int/en>), Online Mendelian Inheritance in Man (OMIM) (www.omim.org), Orphanet (<https://www.orpha.net/consor/cgi-bin/index.php>), UMLS (9) (<https://www.nlm.nih.gov/research/umls/index.html>), MeSH (<https://www.nlm.nih.gov/mesh/meshhome.html>), Medical Dictionary for Regulatory Activities Terminology (MedDRA) (10) (<https://www.meddra.org/>), and Genetic and Rare Diseases (GARD) (<https://rarediseases.info.nih.gov/>). The classification and epidemiology of 86 rare diseases were analyzed through Orphanet database. The genetic information was summarized using OMIM database.

3. Results

3.1. Nomenclature of 86 diseases in *China's Second List of Rare Diseases*

Rare diseases in *China's Second List of Rare Diseases* were mapped to seven different reference databases (Table 1). UMLS coded the most rare diseases ($n = 78$, 90.70%) with a unique identifier, followed by 77 diseases (89.53%) in ORPHAcode, 74 diseases (86.05%) in MeSH, 66 diseases (76.74%) in ICD-11, and 64 diseases (74.42%) in ICD-10, 59 diseases (68.60%) in GARD and 57 diseases (66.28%) in MedDRA (Supplemental Table S1, <https://www.irdrjournal.com/action/getSupplementalData.php?ID=220>). In ICD-10, identifier C49.9 encodes both dermatofibrosarcoma protuberans and epithelioid sarcoma, Lennox-Gastaut syndrome and West syndrome were classified into other generalized epilepsy and epileptic syndromes (G40.4). Bardet-Biedl syndrome and IGF1 deficiency were classified into hypopituitarism in ICD-11 (5A61.0). Except MeSH, melanoma and pemphigus were coded by at least two different codes in all other 6 nomenclature systems. PIK3CA related overgrowth syndrome and was multiple coded in 5 different nomenclature systems.

In Orphanet database, acquired hemophilia, congenital biliary atresia, malignant hyperthermia, melanoma, pemphigus and thalassemia major were coded using more than two different codes. ORPHA163596

and 231214 coded alpha-thalassemia major and beta-thalassemia major, respectively. Syndrome with alpha-thalassemia as a major feature (ORPHA 232288) was a group of disorders consisting of alpha-thalassemia-intellectual disability syndrome linked to chromosome 16 (ORPHA 98791), alpha-thalassemia-myelodysplastic syndrome (ORPHA 231401) and X-linked alpha-thalassemia-intellectual disability syndrome (ORPHA 847). Code 182095 represents a group of disorders of interstitial lung disease (ILD), including interstitial lung disease in childhood and adulthood ORPHA (264757), interstitial lung disease specific to adulthood (ORPHA 264735) and interstitial lung disease specific to childhood (ORPHA 264656).

In ICD-10, nine different diseases were non-coded. Cutaneous neuroendocrine carcinoma, melanoma, pemphigus, pheochromocytoma, PIK3CA related overgrowth syndrome and thalassemia major were coded using more than three different codes. In ICD-11, five diseases were non-coded. Thirteen types of rare tumor were coded using at least two different identifiers. A total of 26 diseases were coded using more than two different identifiers and 13 of them were tumor diseases. In UMLS, gastroenteropancreatic neuroendocrine neoplasm was non-coded. In the databases of MeSH, GARD and MedDRA, a total of 11, 24 and 26 rare diseases were non-coded, respectively (Table 1, Supplemental Table S1, <https://www.irdrjournal.com/action/getSupplementalData.php?ID=220>).

3.2. Classification of 86 diseases in *China's Second List of Rare Diseases*

In the Orphanet classification system of rare diseases, 83 diseases with ORPHAcodes in *China's Second List of Rare Diseases* were mapped (Supplemental Table S2, <https://www.irdrjournal.com/action/getSupplementalData.php?ID=221>). Of these, 45 are genetic rare diseases, accounting for 53.49%. These were followed by 28 (32.56%) neoplastic diseases and transplant-related disorders, respectively; 24 neurological diseases (27.91%), 15 skin diseases (17.44%), 13 renal diseases (15.12%), 12 developmental anomalies during embryogenesis, hepatic diseases, hematological diseases, endocrine diseases, ophthalmic disorders and systemic and rheumatological diseases, each accounting for 13.95% (Table 2).

3.3. Group of rare disorders and genotypic heterozygosity of rare diseases

Some rare diseases are groups of disorders and others have different subtypes according to classification, leading to a higher number of rare diseases in *China's Second List of Rare Diseases* than the actual number (Supplemental Table S3, <https://www.irdrjournal.com/action/getSupplementalData.php?ID=222>). As an

Table 1. Identifiers of 86 rare diseases in China's Second List of Rare Diseases encoded by seven different reference databases

| # | Rare disease | ORPHA | ICD-10 | ICD-11 | UMLS | MeSH | GARD | MedDRA |
|----|--|------------------|-------------------------|--|----------------------|---------|-------|----------------------|
| 1 | Achondroplasia | 15 | Q77.4 | LD24.00 | C0001080 | D000130 | 8173 | C0001080 |
| 2 | Acquired hemophilia | 599480 955485 | D66. X01 | 3B22 | C0272325 C0398609 | C536392 | 6405 | 10082745 10082747 |
| 3 | Acromegaly | 963 | E22.0 | 5A60.0 | C0001206 | D000172 | 5725 | 10000599 |
| 4 | Adult-onset Still disease | 829 | M06.1 | FA23 | C0085253 | D016706 | 436 | 10064056 |
| 5 | Alagille syndrome | 52 | Q44.7 | LB20.0Y | C0085280 | D016738 | 804 | 10053870 |
| 6 | Alpha-1-antitrypsin deficiency | 60 | E88.0 | 5C5A | C0221757 | D019896 | 5784 | 10001806 |
| 7 | ANCA-associated vasculitis | 156152 | - | 4A44.A | C2717865 | D056648 | - | - |
| 8 | Bardet-Biedl syndrome | 110 | Q87.8 | 5A61.0 | C0752166 | D020788 | 6866 | 10056715 |
| 9 | Behçet's disease | 117 | M35.2 | 4A62 | C0004943 | D001528 | 848 | 10004213 |
| 10 | Blue rubber bleb nevus | 1059 | Q27.8 | LC51 | C0346072 | C536240 | 5940 | - |
| 11 | CDKL5-deficiency disorder | 505652 | - | 8A62.Y | C4750718 | C564064 | - | 10083005 |
| 12 | Choroidermia | 180 | H31.2 | 9B61 | C0008525 | D015794 | 6061 | 10008791 |
| 13 | Chronic inflammatory demyelinating polyneuropathy | 2932 | G61.8 | 8C01.3 | C0393819 | D020277 | 6102 | 10057645 |
| 14 | Clear cell sarcoma of kidney | 457246 | C64 | XH0765 | C0334488 | - | - | 10009253 |
| 15 | Cold agglutinin disease | 56425 | D59.1 | 3A20.1 | C0175816 | D000744 | 6130 | - |
| 16 | Congenital biliary atresia | 498345 30391 | Q44.2 | LB20.21 | C5680082 | D001656 | - | - |
| 17 | Congenital factor VII deficiency | 327 | D68.2 | 3B14.7 | C0015503 | D005168 | 2238 | 10016079 |
| 18 | Cryopyrin associated periodic syndrome/ NLRP3-associated systemic autoinflammatory disease | 208650 | - | 4A60.1 | C2316212 | D056587 | 10927 | 10068850 |
| 19 | Cutaneous neuroendocrine carcinoma (Merkel cell carcinoma) | 79140 | C44.3 C44.6 C44.7 | 2C34 XH8IN8 | C0007129 | D015266 | 9266 | - |
| 20 | Cutaneous T-cell lymphomas | 178551 | C84.8 C86.3 C86.6 | XH1951 2B0Y 2B0Z 2B03.0 XH84A5 XH5SC3 XH7S84 XH7EL2 XH2513 | C5680497 | D016410 | - | - |
| 21 | Cystinosis | 213 | E72.0 | 5C60.1 | C4316899 | D003554 | 6236 | 10011777 |
| 22 | Dermatofibrosarcoma protuberans | 31112 | C49.9 | 2B53.Y XH4QZ8 XH5CT4 XH9V92 | C0392784 | D018223 | 9569 | 10057070 |
| 23 | Eosinophilic gastroenteritis | 2070 | K52.8 | DA94.21 | C1262481 | C535952 | - | 10017902 |

Note: "- "indicates no records are available.

Table 1. Identifiers of 86 rare diseases in China's Second List of Rare Diseases encoded by seven different reference databases (continued)

| # | Rare disease | ORPHA | ICD-10 | ICD-11 | UMLS | MeSH | GARD | MedDRA |
|----|---|--------|----------------|--|----------|---------|-------|----------|
| 24 | Epithelioid sarcoma | 293202 | C49.9 | 2B5F.2 XH4F96 XH92Y0 XH4BT2 XH13Z5 | C0205944 | D012509 | 10181 | 10015099 |
| 25 | Facioscapulohumeral muscular dystrophy | 269 | G71.0 | 8C70.3 | C0238288 | D020391 | 9941 | 10064087 |
| 26 | Familial hemophagocytic lymphohistiocytosis | 540 | D76.1 | 4A01.23 | C0272199 | - | 6589 | 10070904 |
| 27 | Familial adenomatous polyposis | 733 | D12.6 | 2B90.Y | C0032580 | D011125 | 6408 | 10056981 |
| 28 | Fibrodysplasia ossificans progressiva | 337 | M61.1 | FB31.1 | C0016037 | D009221 | 6445 | 10068715 |
| 29 | Fragile X syndrome | 908 | Q99.2 | LD55 | C0016667 | D005600 | 6464 | 10017324 |
| 30 | Ganglioidosis | 309144 | E75.1 E75.0 | 5C56.00 | C0017083 | D005733 | 12510 | - |
| 31 | Gastroenteropancreatic neuroendocrine neoplasms | 100092 | - | - | - | - | 2437 | - |
| 32 | Gastrointestinal stromal tumor | 44890 | C26.9 | 2B5B 2B5B.0 2B5B.1 2B5B.Y 2B5B.Z 2E87 | C0238198 | D046152 | 8598 | 10051066 |
| 33 | Generalized pustular psoriasis | 247353 | L40.1 | XH9HQ1 EA90.40 | C0343055 | - | 12819 | - |
| 34 | Genetic hypoparathyroidism | 208593 | - | - | C5680825 | - | - | - |
| 35 | Giant cell arteritis | 397 | M31.6 | 4A44.2 | C0039483 | D013700 | 9615 | 10018250 |
| 36 | Giant cell tumor of bone | 363976 | D48.0 | 2F7B 2F9B | C0206638 | D018212 | - | - |
| 37 | Glanzmann thrombasthenia | 849 | D69.1 | XH0492 XH4TC2 | C0040015 | D013915 | 2478 | - |
| 38 | Glioblastoma | 360 | C71.9 | 2A00.00 XH0MB1 XH17J4 XH2BA5 XH49K9 XH4FN3 XH5571 XH7F82 XH8UC5 2A02.00 | C1621958 | D005909 | 2491 | 10018336 |
| 39 | Gorlin syndrome | 377 | C44.9 | LD2D.4 | C0004779 | D001478 | 7166 | 10062804 |
| 40 | Hidradenitis suppurativa | - | L73.2 | ED92.0 | C0162836 | D017497 | - | - |
| 41 | Hutchinson-Gilford progeria syndrome | 740 | E34.8 | LD2B | C0033300 | D011371 | 7467 | 10036794 |

Note: "- " indicates no records are available.

Table 1. Identifiers of 86 rare diseases in China's Second List of Rare Diseases encoded by seven different reference databases (continued)

| # | Rare disease | ORPHA | ICD-10 | ICD-11 | UMLS | MeSH | GARD | MedDRA |
|----|--|--------|---------|----------------------------|----------|------------|--------|----------|
| 42 | Inflammatory myofibroblastic tumor | 178342 | D48.7 | 2E92.1 2F30.Y XH66Z0 | C0334121 | - | 7146 | 10067917 |
| 43 | Leber congenital amaurosis | 65 | H35.5 | 9B70 | C0339527 | D057130 | 634 | 10070667 |
| 44 | Lennox-Gastaut syndrome | 2382 | G40.4 | 8A62.1 | C0238111 | D065768 | 9912 | 10048816 |
| 45 | Limbal stem cell deficiency | 171673 | H18.7 | - | C1561989 | D000092423 | - | 10072138 |
| 46 | Malignant hyperthermia | 423 | T88.3 | 8C78 | C0024591 | D008305 | - | - |
| | | 46650 | | NE86 | C2930828 | | | |
| 47 | Malignant pleural mesothelioma | 50251 | C45.0 | 2C26.0 | C1377913 | D000086002 | 7026 | 10059518 |
| 48 | Melanoma | 617910 | C43.001 | XH4846 | C0206651 | D008545 | 8621 | 10061252 |
| | | 252031 | C43.101 | XH25M1 | C0220633 | | 120161 | 10066384 |
| | | 404560 | C43.151 | 2C00.1 | C0346360 | | | |
| | | 618 | C43.201 | 2C22.3 | C1512419 | | | |
| | | 293822 | C43.251 | 2C30 | C2314896 | | | |
| | | 168999 | C43.301 | 2C30.0 | C4749348 | | | |
| | | 97338 | C43.302 | 2C30.1 | C4749577 | | | |
| | | 252050 | C43.351 | 2C30.2 | C5191057 | | | |
| | | 39044 | C43.352 | 2C30.3 | | | | |
| | | | C43.401 | 2C30.Y | | | | |
| | | | C43.402 | 2C30.Z | | | | |
| | | | C43.501 | 2C70.1 | | | | |
| | | | C43.551 | 2C71.1 | | | | |
| | | | C43.552 | 2C81.1 | | | | |
| | | | C43.553 | 2D00.0 | | | | |
| | | | C43.601 | 2D01.0 | | | | |
| | | | C43.602 | 2E63 | | | | |
| | | | C43.651 | 2E63.0 | | | | |
| | | | C43.701 | 2E63.OZ | | | | |
| | | | C43.751 | 2E63.1 | | | | |
| | | | C43.752 | 2E63.Y | | | | |
| | | | C43.851 | 2E63.Z | | | | |
| | | | C43.901 | 9B71.40 | | | | |
| | | | C43.902 | | | | | |
| 49 | Metachromatic leukodystrophy | 512 | E75.2 | 5C56.02 | C0023522 | D007966 | 3230 | 10067609 |
| 50 | Mono-genic non-syndromic obesity-Genetic non-syndromic obesity | 98267 | E66.8 | 5B81.Y | C5680229 | - | - | - |

Note: "- " indicates no records are available.

Table 1. Identifiers of 86 rare diseases in China's Second List of Rare Diseases encoded by seven different reference databases (continued)

| # | Rare disease | ORPHA | ICD-10 | ICD-11 | UMLS | MeSH | GARD | MedDRA |
|----|--------------------------------|--------|---------|--|----------|---------|-------|----------|
| 51 | Multiple endocrine neoplasia | 276161 | D44.8 | 2F7A.Y | C0027662 | D009377 | - | 10061299 |
| 52 | Narcolepsy | 619284 | - | 7A20 7A20.0 7A20.1 7A20.Z | C0027404 | D009290 | - | 10028713 |
| 53 | Neuroblastoma | 635 | C74.9 | VV01 2A00.11 XH85Z0 | C0027819 | D009447 | 7185 | 10029260 |
| 54 | Neurofibromatosis | 634518 | Q85.001 | LD2D.1 | C5816781 | D017253 | - | - |
| 55 | Neuronal ceroid lipofuscinosis | 216 | E75.4 | 5C56.1 | C0027877 | D009472 | 10739 | 10074607 |
| 56 | Neurotrophic keratitis | 137596 | H16.2 | 1F00.10 | C0339296 | - | - | 10069732 |
| 57 | Osteosarcoma | 668 | C41.9 | 2B50 2B50.0 2B50.1 2B50.2 2B50.Y 2B50.Z | C0029463 | D012516 | 7284 | 10031291 |
| | | | | XH06W9 XH0Y34 XH1S32 XH1XF3 XH1Y90 XH23T4 XH29N8 XH2CD6 XH3T03 XH48A9 XH4EZ4 XH5CL5 XH5FH4 XH6E77 XH6LT5 XH6TL0 XH7N84 XH7XB9 XH8HG5 XH8J23 XH8X47 XH9119 XH9344 XH9LS2 | | | | |

Note: "-": "indicates no records are available.

Table 1. Identifiers of 86 rare diseases in China's Second List of Rare Diseases encoded by seven different reference databases (continued)

| # | Rare disease | ORPHA | ICD-10 | ICD-11 | UMLS | MeSH | GARD | MedDRA |
|----|--|--|---|---|--|--|-----------------------|--|
| 58 | Pemphigus | 704 2841 46485 63455 79479 79480 79481 208524 555905 636955 | L10.0 L10.1 L10.2 L10.3 L10.4 L10.8 L10.8 L10.8 Q82.8 | EB40.0 EB40.0Y EB40.1 EB40.1 EB40.1 EB40.2 EB40.Y EC20.2 | C0030809 C0085106 C0263312 C0263313 C0263314 C0263316 C1112570 C1274167 C4749730 C5681323 C0031190 C0031511 C0334419 C1302282 | D010392 | 6559 7354 7355 | 10052802 10057053 10057056 10057069 10058917 |
| 59 | Persistent pulmonary hypertension of the newborn | - | P29.3 | KB42 | C5681323 | D010547 | - | - |
| 60 | Pheochromocytoma | - | C74.101 D35.051 | 5A75 XH3854 XH9K97 2D11.1 | C0031190 C0031511 C0334419 C1302282 | D010673 | - | - |
| 61 | PIK3CA related overgrowth syndrome | 530313 | Q04.5 Q74.0 Q74.2 Q87.3 | EF02.1 LA05.1 LB97.1 LD2C LD2F.1Y Q74.0 | C0431391 C1865285 C2751313 C2752042 C4749904 C5192432 C5679987 C5679988 C5680341 | C536142 C567763 C567863 D065705 | 6950 10939 2637 | 10081236 |
| 62 | Polycythaemia vera | 729 | D45 | 2A20.4 | C0032463 | D011087 | 7422 | 10036057 |
| 63 | Primary biliary cholangitis | 186 | K74.3 | DB96.1 DB96.10 DB96.1Y DB96.1Z | C0008312 | D008105 | 7459 | 10080429 |
| 64 | Primary ciliary dyskinesia | 244 | Q34.8 | LA75.Y | C4551720 | D002925 | 4484 | 10069713 |
| 65 | Primary IGF1 deficiency | 73272 | E34.3 | 5A61.0 | C1837475 | C563867 | 10627 | - |
| 66 | Primary immunodeficiency | 101997 | - | L1-4A0 | C0398686 | D000081207 | - | 10064859 |
| 67 | Primary myelofibrosis | 824 | D47.4 | 2A20.2 XH7GG7 | C0001815 | D055728 | 8618 | 10077161 |
| 68 | Primary sclerosing cholangitis | 171 | K83.0 | DB96.20 DB96.2Y DB96.2Z | C0566602 | D015209 | 1280 | 10036732 |

Note: "- " indicates no records are available.

Table 1. Identifiers of 86 rare diseases in China's Second List of Rare Diseases encoded by seven different reference databases (continued)

| # | Rare disease | ORPHA | ICD-10 | ICD-11 | UMLS | MeSH | GARD | MedDRA |
|----|--|--|-------------------------|--|--|------------|-------|----------|
| 69 | Progressive fibrosing interstitial lung disease | 182095 | J84.9 J84.1 | CB03.6 CB04.Y CB04.Z CB05.1 CB05.2 CB05.3 CB05.4 CB05.Y CB05.Z | C0206062 | D017563 | - | 10022611 |
| 70 | Recurrent pericarditis | 251307 | I09.2 | - | C4707790 | - | - | - |
| 71 | Retinopathy of prematurity | 90050 | H35.1 | 9B71.3 | C0035344 | D012178 | 5695 | 10038933 |
| 72 | Rett syndrome | 778 | F84.2 | LD90.4 | C0035372 | D015518 | 5696 | 10039000 |
| 73 | Short bowel syndrome | 104008 | - | DA96.04 | C0036992 | D012778 | 1502 | 10049416 |
| 74 | Systemic juvenile idiopathic arthritis | 85414 | M08.2 | KB89.1 | C0087031 | - | 10966 | 10042061 |
| 75 | Systemic mastocytosis | 2467 | C96.2 | FA24.4 2A21.0 2A21.0Y 2A21.0Z | C0221013 | D034721 | 8616 | 10042949 |
| 76 | Takayasu arteritis | 3287 | M31.4 | XH10N1 XH1H01 XH2Y59 XH5191 | C0039263 | D013625 | 7730 | 10043097 |
| 77 | Tenosynovial giant cell tumor/Pigmented villonodular synovitis | 66627 | M12.2 | 4A44.1 XH6911 XH0HZ1 XH52J9 XH5AQ9 | C1318543 | D000070779 | 7396 | - |
| 78 | Thalassemia major | 163596 231214 98791 231401 847 | D46.7 D56.0 D56.1 | 3A50.03 3A50.0Y 3A50.1 3A50.2 D56.0 | C5680928 C0002875 C0272005 C0585216 C0795917 C1845055 | D017086 | 5864 | - |
| 79 | Thrombotic thrombocytopenic purpura | 54057 | M31.1 | 3B64.14 | C0034155 | D011697 | - | 10043648 |
| 80 | Transferrin amyloidosis | 271861 | - | 5D00.20 BC43.20 4A60.2 | C5679761 | C567782 | - | - |
| 81 | Tumor necrosis factor receptor associated periodic syndrome | 32960 | E85.0 | 4A60.2 | C1275126 | - | 8457 | - |
| 82 | Tumor-induced osteomalacia | 352540 | M83.8 | - | C1274103 | C537751 | 9652 | - |
| 83 | Von Hippel-Lindau syndrome | 892 | Q85.8 | 5A75 | C0019562 | D006623 | 7855 | 10047716 |
| 84 | Von Willebrand disease type3 | 166096 | D68.0 | 3B12 | C1264041 | D056729 | - | - |

Note: "- " indicates no records are available.

Table 1. Identifiers of 86 rare diseases in China's Second List of Rare Diseases encoded by seven different reference databases (continued)

| # | Rare disease | ORPHA | ICD-10 | ICD-11 | UMLS | MeSH | GARD | MedDRA |
|----|---|-------|--------|----------------------------|----------|---------|------|----------|
| 85 | Waldenström macroglobulinemia/ Lymphoplasmacytic lymphoma | 33226 | C88.0 | XH8GW4 2A85.4 XH0QZ9 | C0024419 | D008258 | 7872 | 10047801 |
| 86 | West syndrome/Infantile spasms syndrome | 3451 | G40.4 | 8A62.0 | C0037769 | D013036 | 7887 | 10021750 |

Note: "-": indicates no records are available.

Table 2. The number and percentage of 86 rare diseases in China's Second List of Rare according to classification system in Orphanet database

| Orphanet classification | number | Percentage (%) |
|---|--------|----------------|
| genetic diseases | 45 | 52.35 |
| neoplastic diseases | 28 | 32.56 |
| transplant-related disorders | 28 | 32.56 |
| neurological diseases | 24 | 27.91 |
| skin diseases | 15 | 17.44 |
| renal diseases | 13 | 15.12 |
| developmental anomalies during embryogenesis | 12 | 13.95 |
| hematological diseases | 12 | 13.95 |
| endocrine diseases | 12 | 13.95 |
| ophthalmic disorders | 12 | 13.95 |
| systemic and rheumatological diseases | 12 | 13.95 |
| bone diseases | 7 | 8.14 |
| respiratory diseases | 7 | 8.14 |
| systemic or rheumatologic diseases of childhood | 7 | 8.14 |
| hepatic diseases | 5 | 5.81 |
| circulatory system diseases | 5 | 5.81 |
| inborn errors of metabolism | 5 | 5.81 |
| gastroenterological diseases | 5 | 5.81 |
| immunological diseases | 4 | 4.65 |
| infertility disorders | 3 | 3.45 |
| abdominal surgical diseases | 2 | 2.33 |
| cardiac malformations | 1 | 1.16 |
| gynecological and obstetric diseases | 1 | 1.16 |

example, primary immunodeficiency (ORPHA 101997) includes primary immunodeficiency owing to a defect in adaptive immunity (ORPHA 179006) and primary immunodeficiency owing to a defect in innate immunity (ORPHA 101988). The former group includes combined T- and B-cell immunodeficiency (ORPHA 101972), immune dysregulation disease with immunodeficiency (ORPHA 169361), immunodeficiency predominantly affecting antibody production (ORPHA 101977), and combined immunodeficiency (ORPHA 331217). The latter group includes autoinflammatory syndrome with immune deficiency (ORPHA 290839), genetic susceptibility to infections owing to particular pathogens (ORPHA 183710), immunodeficiency owing to a complement cascade protein anomaly (ORPHA 101992), other immunodeficiency syndromes owing to defects in innate immunity (ORPHA 331193), primary immunodeficiency with predisposition to severe viral infection (ORPHA 431156), and quantitative and/or qualitative congenital phagocyte defect (ORPHA 101985).

Genetic rare diseases in the second list are summarized in Supplemental Table S4 (<https://www.irdrjournal.com/action/getSupplementalData.php?ID=223>). Inheritance, phenotype, and pathogenic genes are included in the table as data collected from the OMIM database. Some rare diseases are caused by mutation of single genes and others are caused by mutation in multiple genes. A total of 53 different phenotypes with 49 pathogenic genes exist in primary ciliary dyskinesia, in both the autosomal recessive

(AR), autosomal dominant (AD) or X-linked recessive inheritance format. Bardet–Biedl syndrome (BBS) is inherited mainly in the form of AR with 22 different phenotypes and 24 genes. Phenotype BBS1 corresponds to three different pathogenic genes *CCDC28B*, *ARL6*, and *BBS1*, with AD or AR inheritance patterns. The phenotype BBS14 corresponds to the *TMEM67* and *CEP290* genes inherited in AR form. The *ARL6* gene corresponds to phenotypes of both BBS1 and BBS3. There are 20 different genes and a corresponding 18 phenotypes in Leber congenital amaurosis. For neuronal ceroid lipofuscinosis, a total of 12 genes corresponds to 14 different subtypes and phenotypes. For Alagille syndrome, three subtypes are classified according to different pathogenic genes with microdeletion in 20p12, *JAG1*, and *NOTCH2*. In summary, genotypic and phenotypic heterozygosity exist among these rare diseases.

3.4. Epidemiology of diseases in *China's Second List of Rare Diseases*

According to data from Orphanet, the epidemiology of the 86 rare diseases is described in Table 3. Data on the newborn incidence, incidence, and prevalence of 71 rare diseases (82.56%) in *China's Second List of Rare Diseases* are available, including data on the newborn incidence of 7 (8.14%), incidence of 20 rare diseases (23.26%) and the prevalence of 64 (74.42%) rare diseases. As we mentioned above (also see Supplementary Table S3 (<https://www.irdrjournal.com/action/getSupplementalData.php?ID=222>), some rare disorders are groups composed of different disorders with some correlations, hence, only disorders in the group with epidemiological data were collected. Newborn incidence of 0.6/100,000 in the pediatric population and incidence of 1.6-23/100,000 per year in children were reported in systemic juvenile idiopathic arthritis. The birth incidence of familial adenomatous polyposis was as high as 12.05/100,000. In all, an annual incidence of 20 rare diseases available in Orphanet, a relatively broad newborn incidence was observed in malignant hyperthermia of anesthesia, systemic juvenile idiopathic arthritis, primary biliary cholangitis, polycythaemia vera, Lennox-Gastaut syndrome and cutaneous neuroendocrine carcinoma (Merkel cell carcinoma). The annual incidence of beta-thalassemia major is estimated at 1/100,000 worldwide and 1/10,000 in the European population.

A total of 23 rare diseases or its subtypes showed a prevalence of higher than 1/10,000 including alpha-1-antitrypsin deficiency, ANCA-associated vasculitis, dermatofibrosarcoma protuberans, Fragile X syndrome, neuroendocrine tumor of pancreas, gastrointestinal stromal tumor, giant cell arteritis, Lennox-Gastaut syndrome, Limbal stem cell deficiency, narcolepsy type 1, neuroblastoma, neurotrophic keratitis, pemphigus vulgaris, polycythaemia vera, primary biliary

cholangitis, retinopathy of prematurity, gastroschisis, systemic mastocytosis, tenosynovial giant cell tumor (pigmented villonodular synovitis), Hb Bart's hydrops fetalis and thrombotic thrombocytopenic purpura. For thrombotic thrombocytopenic purpura (TTP), the prevalence of iTTP was 14.29/100,000, which is higher than that of the cTTP type. Thirty-five different rare diseases had a prevalence of less than 10/100,000 and greater than or equal to 1/100,000, these included acromegaly, adult-onset Still disease, Bardet-Biedl syndrome, Behçet's disease, CDKL5-deficiency disorder, choroideremia, chronic inflammatory demyelinating polyneuropathy, biliary atresia, cutaneous neuroendocrine carcinoma, cystinosis, eosinophilic gastroenteritis, facioscapulohumeral muscular dystrophy, familial adenomatous polyposis, glioblastoma, Gorlin syndrome, Leber congenital amaurosis, malignant pleural mesothelioma, multiple endocrine neoplasia, and so on. Epithelioid sarcoma, Hutchinson–Gilford progeria syndrome, primary IGF1 deficiency, fibrodysplasia ossificans progressiva, hypoplastic pancreas-intestinal atresia-hypoplastic gallbladder syndrome, cold agglutinin disease, congenital factor VII deficiency and another 13 rare diseases had relatively low prevalence at less than 1/100,000.

4. Discussion

The study nominated the 86 diseases in *China's Second List of Rare Diseases* using different reference systems. The results showed that most rare diseases have unique identifiers, especially in the Orphanet database. Orphanet nomenclature is a powerful classification tool based on the multidimensional nature of rare diseases, which provides a specific terminology for rare diseases. Each clinical entity is assigned a unique and time-stable ORPHAcode. This includes all disorders, subtypes of disorders, and groups of disorders. Over 6000 rare diseases are coded using ORPHAcodes (11). ORPHAcodes have high sensitivity and accuracy in describing rare diseases. More than half of ORPHAcodes identify diseases with very low prevalence (less than 1 case per million) (12). The International Classification of Diseases is a medical classification list produced by the World Health Organization that is predominantly used in health care systems worldwide. However, less rare diseases are listed in versions older than ICD-10. One ICD code can correspond to different rare entities or to both rare and non-rare entities. This is often not clearly distinguished in health information systems (13,14). ICD-11 was adopted by the World Health Assembly in May 2019 and came into effect in January 2022. This version includes nearly 5,500 rare diseases and each has a unique identifier. Rare diseases in ICD-11 are easily available in health information systems and are continually updated (5,14). It has a unique identifier for different subtypes of one disease and different conditions

Table 3. Incidence and prevalence of 86 rare diseases in China's Second List of Rare Diseases recorded in Orphanet database

| # | Rare diseases | Newborn Incidence / 100,000 persons | Incidence / 100,000 persons | Prevalence / 100,000 persons |
|----|--|-------------------------------------|------------------------------------|--|
| 1 | Achondroplasia | 4 | - | - |
| 2 | Acquired hemophilia A | - | - | - |
| | Acquired hemophilia B | - | - | - |
| | hemophilia C | - | - | 0.1-0.9 |
| 3 | Acromegaly | - | 0.19-1.1 (annual) | 1-9 |
| 4 | Adult-onset Still disease | - | - | 1-9 |
| 5 | Alagille syndrome | - | - | 1.43 |
| 6 | Alpha-1-antitrypsin deficiency | - | - | 10-50 |
| 7 | ANCA-associated vasculitis | - | - | 10-50 |
| | Eosinophilic granulomatosis with polyangiitis | - | - | 1-9 |
| | Granulomatosis with polyangiitis | - | 0.21-1.19 | 1-9 |
| | Microscopic polyangiitis | - | - | 1-9 |
| 8 | Bardet-Biedl syndrome | - | - | 1 (USA) 1.69 (Denmark) 1.52-2.22 (France) |
| 9 | Behçet's disease | - | - | 1-9 |
| 10 | Blue rubber bleb nevus | - | - | - |
| 11 | CDKL5-deficiency disorder | - | - | 2.36 (UK (Scotland) birth prevalence |
| 12 | Choroideremia | - | - | 1-9 |
| 13 | Chronic inflammatory demyelinating polyneuropathy | - | - | 1-9 |
| 14 | Clear cell sarcoma of kidney | - | - | - |
| 15 | Cold agglutinin disease | - | - | 0.1-0.9 |
| 16 | biliary atresia | - | - | - |
| | Isolated biliary atresia | - | - | 1-9 |
| | Biliary atresia with splenic malformation syndrome | - | - | - |
| | Hypoplastic pancreas-intestinal atresia-hypoplastic gallbladder syndrome | - | - | < 0.1 |
| 17 | Congenital factor VII deficiency | - | - | 0.1-0.9 |
| 18 | Cryopyrin associated periodic syndrome- NLRP3-associated systemic autoinflammatory disease | - | - | 0.28 (France) |
| | CINCA syndrome | - | - | 0.28 (the whole spectrum of CAPS) |
| | Familial cold urticaria | - | - | - |
| | Muckle-Wells syndrome | - | - | 0.28 (France) |
| 19 | Cutaneous neuroendocrine carcinoma (Merkel cell carcinoma) | - | 0.2-0.4 (annual, white population) | 1-9 |
| 20 | Cutaneous T-cell lymphomas | - | - | - |
| | Mycosis fungoides and variants | - | 0.29-0.91 | - |
| | Primary cutaneous CD30+ T-cell lymphoproliferative disease | - | - | - |
| | Adult T-cell leukemia-lymphoma | - | - | 1-9 |
| 21 | Cystinosis | - | - | 1-9 |
| 22 | Dermatofibrosarcoma protuberans | - | 0.5 | 10-50 |
| 23 | Eosinophilic gastroenteritis | - | - | - |
| 24 | Epithelioid sarcoma | - | - | < 0.1 |
| 25 | Facioscapulohumeral muscular dystrophy | - | - | 1-9 |
| 26 | Familial hemophagocytic lymphohistiocytosis | - | - | - |
| 27 | Familial adenomatous polyposis | 12.05 | - | 1-9 |
| 28 | Fibrodysplasia ossificans progressiva | - | - | < 0.1 |
| 29 | Fragile X syndrome | - | - | 10-50 |
| 30 | Gangliosidosis | - | - | - |
| | GM1 gangliosidosis | - | - | 0.5-1 (live births) |
| | GM1 gangliosidosis type 1 | - | - | 0.5-1(live births) |
| | GM1 gangliosidosis type 2 | - | - | < 0.1 |
| | GM1 gangliosidosis type 3 | - | - | < 0.1 |
| | GM2 gangliosidosis | - | - | 1-9 |
| | GM2 gangliosidosis, AB variant | - | - | < 0.1 |
| | Sandhoff disease | - | - | 0.1-0.9 |
| | Tay-Sachs disease | - | - | - |
| 31 | Gastroenteropancreatic neuroendocrine neoplasm | - | - | - |
| | Neuroendocrine tumor of stomach | - | - | 1-9 |
| | Neuroendocrine carcinoma of pancreas | - | - | - |
| | Neuroendocrine tumor of pancreas | - | - | 10-50 |
| 32 | Gastrointestinal stromal tumor | - | - | 10-50 |
| 33 | Generalized pustular psoriasis | - | - | 0.1-0.9 |

Table 3. Incidence and prevalence of 86 rare diseases in China's Second List of Rare Diseases recorded in Orphanet database (continued)

| # | Rare diseases | Newborn Incidence / 100,000 persons | Incidence / 100,000 persons | Prevalence / 100,000 persons |
|----|---|--|--|---------------------------------|
| 34 | Genetic hypoparathyroidism | - | - | - |
| | Autoimmune polyendocrinopathy type 1 | - | - | 0.1-0.9 |
| | Familial isolated hypoparathyroidism | - | - | < 0.1 |
| | Pseudohypoparathyroidism | - | - | 0.1-0.9 |
| 35 | Giant cell arteritis | - | 5.88-20 (annual, adults over 50 years old) | 10-50 |
| 36 | Giant cell tumor of bone | - | - | - |
| 37 | Glanzmann thrombasthenia | - | - | - |
| 38 | Glioblastoma | - | 3 | 1-9 |
| 39 | Gorlin syndrome | - | - | 1-9 |
| 40 | Hidradenitis suppurativa | - | - | - |
| 41 | Hutchinson-Gilford progeria syndrome | - | - | < 0.1 |
| 42 | Inflammatory myofibroblastic tumor | - | - | - |
| 43 | Leber congenital amaurosis | - | - | 1-9 |
| 44 | Lennox-Gastaut syndrome | - | 0.1-0.28 | 10-50 |
| 45 | Limbic stem cell deficiency | - | - | 10-50 |
| 46 | Malignant hyperthermia | - | - | - |
| | Malignant hyperthermia of anesthesia | - | 45342 | - |
| 47 | Malignant pleural mesothelioma | - | - | - |
| 48 | Melanoma | - | - | - |
| | Conjunctival malignant melanoma | - | - | < 0.1 |
| | Malignant melanoma of the mucosa | - | - | - |
| | Uveal melanoma | - | - | 1-9 |
| 49 | Metachromatic leukodystrophy | - | - | 0.1-0.9 |
| 50 | Monogenic non-syndromic obesity-Genetic non-syndromic obesity | - | - | - |
| 51 | Multiple endocrine neoplasia | - | - | 3.33-10 (MEN1) 2.86 (MEN2) |
| 52 | Narcolepsy | - | - | - |
| | Narcolepsy type 1 | - | - | 10-50 |
| | Narcolepsy type 2 | - | - | - |
| 53 | Neuroblastoma | - | 1.43 (annual, 15 years old) | 10-50 |
| 54 | Neurofibromatosis | - | - | - |
| | Full NF2-related schwannomatosis | - | - | 1-9 |
| | Full schwannomatosis | - | - | - |
| | Neurofibromatosis type 1 | - | - | 10-50 |
| 55 | Neuronal ceroid lipofuscinosis | - | - | 1-9 |
| | ATP13A2-related juvenile neuronal ceroid lipofuscinosis | - | - | < 0.1 |
| | Congenital neuronal ceroid lipofuscinosis | - | - | - |
| | Infantile neuronal ceroid lipofuscinosis | 5 (Finland) | - | - |
| | Juvenile neuronal ceroid lipofuscinosis | 2.22 (Sweden) 6.99 (Germany) | - | 0.46 (Sweden) |
| | Late infantile neuronal ceroid lipofuscinosis | - | - | 0.3 (Sweden) |
| 56 | Neurotrophic keratitis | - | - | 42.02 (Europe) |
| 57 | Osteosarcoma | - | 0.3 (annual) | 1-9 |
| 58 | Pemphigus | - | - | / |
| | Endemic pemphigus foliaceus | - | - | - |
| | Pemphigus foliaceus | - | - | - |
| | Pemphigus vulgaris | - | 0.07-0.7 (annual) | 10-50 |
| 59 | Persistent pulmonary hypertension of the newborn | - | - | - |
| 60 | Pheochromocytoma | - | - | - |
| 61 | PIK3CA related overgrowth syndrome | - | - | - |
| | CLAPO syndrome | - | - | < 0.1 |
| | CLOVES syndrome | - | - | < 0.1 |
| | Congenital infiltrating lipomatosis of the face | - | - | < 0.1 |
| | Hemihyperplasia-multiple lipomatosis syndrome | - | - | < 0.1 |
| | Megalencephaly-capillary malformation-polymicrogyria syndrome | - | - | < 0.1 |
| | Segmental progressive overgrowth syndrome with fibroadipose hyperplasia | - | - | < 0.1 |
| 62 | Polycythaemia vera | - | 1-2.78 | 10-50 |
| 63 | Primary biliary cholangitis | - | 0.33-5.8(annual) | 10-50 |
| 64 | Primary ciliary dyskinesia | 3.33-6.67 | - | - |

Table 3. Incidence and prevalence of 86 rare diseases in *China's Second List of Rare Diseases* recorded in Orphanet database (continued)

| # | Rare diseases | Newborn Incidence / 100,000 persons | Incidence / 100,000 persons | Prevalence / 100,000 persons |
|----|--|--|--|---|
| 65 | Primary IGF1 deficiency | - | - | < 0.1 |
| 66 | Primary immunodeficiency | - | - | 1-9 |
| 67 | Primary myelofibrosis | - | 1 (annual) | 1-9 |
| 68 | Primary sclerosing cholangitis | - | - | 1-9 |
| 69 | Interstitial lung disease | - | - | - |
| 70 | Recurrent pericarditis | - | - | - |
| 71 | Retinopathy of prematurity | - | - | 10-50 |
| 72 | Rett syndrome | - | - | 1-9 |
| 73 | Short bowel syndrome | - | - | 1-9 |
| | Gastroschisis | - | - | 10-50 |
| | Small bowel atresia | - | - | 4-14.29 (live births, Europe) |
| 74 | Systemic juvenile idiopathic arthritis | 0.6 (prediatric population) | 1.6-23 (annual) | 1-9 |
| 75 | Systemic mastocytosis | - | - | 10-50 |
| | Aggressive systemic mastocytosis | - | - | 0.1-0.9 |
| | Indolent systemic mastocytosis | - | - | 10-50 |
| | Systemic mastocytosis with associated hematologic neoplasm | - | - | 1-9 |
| | Mast cell leukemia | - | - | < 0.1 |
| | Acute mast cell leukemia | - | - | - |
| 76 | Takayasu arteritis | - | - | 1-9 |
| 77 | Tenosynovial giant cell tumor-Pigmented villonodular synovitis | - | - | 10-50 |
| 78 | Thalassemia major | - | - | - |
| | Beta-thalassemia major | - | 1 (worldwide) 10 (EU) | - |
| | Hb Bart's hydrops fetalis | - | - | 50-500 (live births, Southeast Asia) |
| 79 | Thrombotic thrombocytopenic purpura | 0.1-0.61(iTTP) | - | 1.29 (iTTP, France) 0.04-1.67 (cTTP) |
| 80 | Transthyretin amyloidosis | - | - | 0.1-0.9 |
| | ATTRV30M amyloidosis | - | 0.87 (annual, Portugal) | 22.94 (adults) |
| 81 | Tumor necrosis factor receptor associated periodic syndrome | - | 0.57 (annual, children under 16, Germany) | - |
| 82 | Tumor-induced osteomalacia | - | - | - |
| 83 | Von Hippel-Lindau syndrome | 2.78 | - | 1-9 |
| 84 | Von Willebrand disease type3 | - | - | 0.1-0.9 |
| 85 | Waldenström macroglobulinemia- Lymphoplasmacytic lymphoma | - | 0.38 (annual, USA) | 0.99 (Europe) |
| 86 | West syndrome-Infantile spasms syndrome | - | - | 1-9 |

in a group. ICD-11, Orphanet, OMIM, MalaCards and other databases all cross-reference each other.

According to global epidemiologic data and the 2021 definition of rare diseases, conditions with a relatively high newborn incidence and/or prevalence (1/10,000) are recorded in *China's Second List of Rare Diseases*. Data on these registered rare diseases are readily available to advance research and development of orphan drugs and treatments for rare diseases.

In conclusion, in this study, we reviewed the classification, nomenclature, and epidemiology of 86 rare diseases in *China's Second List of Rare Diseases*. Including the 121 rare diseases in the first list, a total of 207 rare diseases have been described by the Chinese government. Administrative policies regarding rare diseases have been enacted, which refer to research, medical insurance, orphan drugs, and standards for diagnosis and treatment. These policies make important

contributions to progress in the area of rare diseases in China. The diseases on China's second list are important research topics and focusing on these will help China become a healthcare model with respect to rare diseases. The inclusion of conditions with relatively higher prevalence than those included in the current definitions will benefit more patients with rare diseases. With further development of national registries, rare diseases with very low prevalence will likely emerge.

Funding: This work was supported by a grant from the Natural Science Foundation of Shandong Province (General program ZR2023MH276) and Academic Promotion Program of Shandong First Medical University (LJ001).

Conflict of Interest: The authors have no conflicts of interest to disclose.

References

1. Shourick J, Wack M, Jannot AS. Assessing rare diseases prevalence using literature quantification. *Orphanet J Rare Dis.* 2021; 16:139.
2. Zhi W, Liu M, Yang D, Zhang S, Lu Y, Han J. Analysis of marketed orphan drugs in China. *Intractable Rare Dis Res.* 2023; 12:132-140.
3. Li X, Wu L, Yu L, He Y, Wang M, Mu Y. Policy analysis in the field of rare diseases in China: A combined study of content analysis and Bibliometrics analysis. *Front Med (Lausanne).* 2023; 10:1180550.
4. He J, Kang Q, Hu J, Song P, Jin C. China has officially released its first national list of rare diseases. *Intractable Rare Dis Res.* 2018; 7:145-147.
5. World Health Organization. Rare diseases. <https://www.who.int/standards/classifications/frequently-asked-questions/rare-diseases> (accessed October 2, 2024).
6. Lu Y, Han J. The definition of rare disease in China and its prospects. *Intractable Rare Dis Res.* 2022; 11:29-30.
7. World Health Organization. ICD-10 Version:2019. <https://icd.who.int/browse10/2019/en> (accessed October 4, 2024).
8. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD). <https://www.who.int/standards/classifications/classification-of-diseases> (accessed October 4, 2024).
9. Bodenreider O. The Unified Medical Language System (UMLS): Integrating biomedical terminology. *Nucleic Acids Res.* 2004; 32:D267-D270.
10. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). *Drug Saf.* 1999; 20:109-117.
11. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y, Rath A. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. *Eur J Hum Genet.* 2020; 28:165-173.
12. Mazzucato M, Pozza LVD, Facchin P, *et al.* ORPHAcodes use for the coding of rare diseases: Comparison of the accuracy and cross country comparability. *Orphanet J Rare Dis.* 2023; 18:267.
13. Rath A, Aymé S, Bellet B. Classification of rare diseases: A worldwide effort to contribute to the International Classification of Diseases. *Orphanet J Rare Dis.* 2010; 5:O21.
14. Aymé S, Bellet B, Rath A. Rare diseases in ICD11: Making rare diseases visible in health information systems through appropriate coding. *Orphanet J Rare Dis.* 2015; 10:35.
15. Jia J, An Z, Ming Y, Guo Y, Li W, Liang Y, Guo D, Li X, Tai J, Chen G, Jin Y, Liu Z, Ni X, Shi T. eRAM: Encyclopedia of rare disease annotations for precision medicine. *Nucleic Acids Res.* 2018; 46:D937-D943.

Received November 2, 2024; Revised November 21, 2024; Accepted November 25, 2024.

§These authors contributed equally to this work.

*Address correspondence to:

Yanqin Lu, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, No. 16766 Jingshi Road, Ji'nan, Shandong 250013, China.

E-mail: yqlu@sdfmu.edu.cn

Released online in J-STAGE as advance publication November 29, 2024.